Heart

for life.

A one-time gene therapy designed to restore the heart’s energy and strength.

Our Science
Our Team

6.7M

Americans living with heart failure today

U.S. PREVALENCE

100K

Daily heartbeats

WORKLOAD

~6kg

ATP produced by the heart, every day

ENERGETIC DEMAND

425K

Annual deaths contributed to by heart failure

HIGH MORTALITY

Current treatments manage heart failure

We aim to restore the heart’s strength and performance. Heart failure remains a condition where the heart cannot pump enough blood to meet the body’s needs – driven by impaired mitochondrial function, weakened contractility, and a self-reinforcing cycle of metabolic decline. Today’s standard of care suppresses neurohormonal signaling. It does not repair the muscle.

CURRENT STANDARD OF CARE

  • Targets neurohormonal signals, not the muscle
  • Daily drug dependence
  • Recurrent hospitalizations

  • 50% five-year mortality rate

OUR PROPOSED APPROACH

  • Restores energetic and contractile function

  • Single, or very few, lifetime doses

  • Prolonged endurance and quality of life

  • Potential to prevent heart failure in early-diagnosis cohorts

Targeting the root biology of heart failure

Heart failure is driven by two coupled deficits – impaired energy production and weakened contraction. In preclinical models, Vectorial’s molecule enters cardiac muscle cells, activates a native master regulator of energy and mechanical performance, and restores function throughout the cardiac contraction cycle.

A unique dual-action mechanism

Heart failure couples impaired energy production with weakened contraction. Existing therapies target neither at the cellular level. We target both – simultaneously, with one regulator.

A biologically grounded target

Vectorial’s molecule is a naturally occurring regulator of energy production and mechanical function. Restoring it works with the heart’s biology rather than overriding it – a precision-medicine route to durable rescue.

Targeted gene therapy

Using engineered AAV vectors, we enable precise, long-lasting expression from a single or infrequent dose with sustained cardiac performance.

Helping hearts beat stronger again by restoring energy and strength.

SUPPORTED BY

In The News

Heart

for life.

A one-time gene therapy designed to restore the heart’s energy and strength.

Our Science
Our Team

6.7M

Americans living with heart failure today

U.S. PREVALENCE

100K

Daily heartbeats

WORKLOAD

~6kg

ATP produced by the heart, every day

ENERGETIC DEMAND

425K

Annual deaths contributed to by heart failure

HIGH MORTALITY

Current treatments manage heart failure

We aim to restore the heart’s strength and performance. Heart failure remains a condition where the heart cannot pump enough blood to meet the body’s needs – driven by impaired mitochondrial function, weakened contractility, and a self-reinforcing cycle of metabolic decline. Today’s standard of care suppresses neurohormonal signaling. It does not repair the muscle.

STANDARD OF CARE

  • Targets neurohormonal signals, not the muscle
  • Daily drug dependence
  • Recurrent hospitalizations

  • 50% five-year mortality rate

OUR APPROACH

  • Restores energetic and contractile function

  • Single, or very few, lifetime doses

  • Prolonged endurance and quality of life

  • Potential to prevent heart failure in early-diagnosis cohorts

Targeting the root biology of heart failure

Heart failure is driven by two coupled deficits – impaired energy production and weakened contraction. In preclinical models, Vectorial’s molecule enters cardiac muscle cells, activates a native master regulator of energy and mechanical performance, and restores function throughout the cardiac contraction cycle.

A unique dual-action mechanism

Heart failure couples impaired energy production with weakened contraction. Existing therapies target neither at the cellular level. We target both – simultaneously, with one regulator.

A biologically grounded target

Vectorial’s molecule is a naturally occurring regulator of energy production and mechanical function. Restoring it works with the heart’s biology rather than overriding it – a precision-medicine route to durable rescue.

Targeted gene therapy

Using engineered AAV vectors, we enable precise, long-lasting expression from a single or infrequent dose with sustained cardiac performance.

Helping hearts beat stronger again by restoring energy and strength